Last reviewed · How we verify
Infanrix IPV
Infanrix IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and inactivated poliovirus.
Infanrix IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and inactivated poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.
At a glance
| Generic name | Infanrix IPV |
|---|---|
| Also known as | DTPa-IPV (GSK Biologicals) |
| Sponsor | GlaxoSmithKline |
| Drug class | combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens. This provides immunological protection against diphtheria, tetanus, pertussis, and poliomyelitis.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers (PHASE2, PHASE3)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa (PHASE4)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (PHASE3)
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers (PHASE4)
- Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |